Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction Save
JAMA Internal Medicine has published a review showing that most currently approved therapies for fibromyalgia (FM) do not have high-quality evidence to support their use; with some reducing pain or improving quality of life (QOL) in the short term, but overall effect size is not impressive. The best (strong evidence) was seen for only cognitive behavioral therapy for pain.
This systematic review and meta-analysis sought to assess effectiveness of therapies for reducing pain and improving quality of life (QOL) in FM. A metanalysis included 224 trials and 29 962 participants.
High-quality evidence was found in favor of cognitive behavioral therapy and antidepressants for pain in the short term.
Also favorable were central nervous system depressants and antidepressants for pain in the medium term.
Overall, there was little evidence of effect for long-term outcomes.